{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:11:45Z","timestamp":1793293905525,"version":"4.5.0"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>The CytoSorb hemoadsorption device (CytoSorbents Inc, Monmouth Junction, NJ) is increasingly used in many critical disease states. The potential impact on the pharmacokinetic (PK) of concomitantly administered drugs must be considered in clinical practice. The current review summarizes relevant mechanistic principles, available preclinical and clinical data, and provides general guidance for the management of concomitant drug administration during CytoSorb therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA SOURCES:<\/jats:title>\n                    <jats:p>Detailed search strategy using the PubMed and OVID MEDLINE databases, as well as presented congress abstracts for studies on drug removal by the CytoSorb device.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>STUDY SELECTION:<\/jats:title>\n                    <jats:p>Human, animal, and bench-top studies with PK or drug-removal data during CytoSorb therapy were selected for inclusion. Publications reporting on CytoSorb treatments for drug overdose were not considered.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA EXTRACTION:<\/jats:title>\n                    <jats:p>Relevant PK data were examined and synthesized for narrative review.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA SYNTHESIS:<\/jats:title>\n                    <jats:p>To date, PK data during CytoSorb hemoadsorption are available for more than 50 drugs, including analgesics, antiarrhythmics, anticonvulsants, antidepressants, antihypertensives, antiinfectives, antithrombotics, anxiolytics, and immunosuppressants. Based on available PK data, drugs were categorized into low (&lt;30%), moderate (30\u201360%), or high rates of removal (&gt;60%), or, alternatively, according to clearance increase relative to endogenous clearance: negligible (&lt;25%), low (25\u2013100%), moderate (100\u2013400%), or high (&gt;400%). In most reports, additional impact of the extracorporeal platform where CytoSorb was integrated was not available. Based on available data and considering drug, patient, and setup-specific aspects, general dosing guidance for clinical practice was developed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>CytoSorb therapy may increase drug elimination through active removal. However, the extent of removal is heterogeneous, and its clinical significance, if any, depends on the broader clinical context, including a patient\u2019s specific endogenous drug clearance and the underlying extracorporeal platform used. The available data, although not definitive, allow for general guidance on dosing adjustments during CytoSorb therapy; however, any treatment decisions should always be complemented by clinical judgment and therapeutic drug monitoring, when available.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/cce.0000000000000688","type":"journal-article","created":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T19:00:05Z","timestamp":1652122805000},"page":"e0688","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":30,"title":["Mechanistic Considerations and Pharmacokinetic Implications on Concomitant Drug Administration During CytoSorb Therapy"],"prefix":"10.1097","volume":"4","author":[{"given":"Joerg","family":"Scheier","sequence":"first","affiliation":[{"name":"CytoSorbents Europe GmbH, Berlin, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Nelson","sequence":"additional","affiliation":[{"name":"CytoSorbents Corporation, Monmouth Junction, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Colombier","sequence":"additional","affiliation":[{"name":"Department of Cardiac Surgery, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Detlef","family":"Kindgen-Milles","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, University Hospital Duesseldorf, Duesseldorf, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efthymios N.","family":"Deliargyris","sequence":"additional","affiliation":[{"name":"CytoSorbents Corporation, Monmouth Junction, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas D.","family":"Nolin","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Therapeutics, Department of Medicine Renal-Electrolyte Division, University of Pittsburgh, Pittsburgh, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,5,9]]},"reference":[{"key":"R1-20240807","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.athoracsur.2018.12.032","article-title":"Cytosorb adsorption during emergency cardiac operations in patients at high risk of bleeding.","volume":"108","author":"Hassan","year":"2019","journal-title":"Ann Thorac Surg"},{"key":"R2-20240807","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/s00134-018-5464-6","article-title":"Hemoadsorption with CytoSorb\u00ae.","volume":"45","author":"Poli","year":"2019","journal-title":"Intensive Care Med"},{"key":"R3-20240807","first-page":"7769516","article-title":"The use of CytoSorb therapy in critically ill COVID-19 patients: Review of the rationale and current clinical experiences.","volume":"2021","author":"Ruiz-Rodr\u00edguez","year":"2021","journal-title":"Crit Care Res Pract"},{"key":"R5-20240807","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3109\/15563650.2012.683436","article-title":"The EXTRIP (EXtracorporeal TReatments In Poisoning) workgroup: Guideline methodology.","volume":"50","author":"Lavergne","year":"2012","journal-title":"Clin Toxicol (Phila)"},{"key":"R7-20240807","doi-asserted-by":"crossref","first-page":"10493","DOI":"10.1038\/s41598-021-89965-z","article-title":"Pharmacokinetics of anti-infective agents during CytoSorb hemoadsorption.","volume":"11","author":"Schneider","year":"2021","journal-title":"Sci Rep"},{"key":"R8-20240807","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1159\/000063108","article-title":"In vitro removal of therapeutic drugs with a novel adsorbent system.","volume":"20","author":"Reiter","year":"2002","journal-title":"Blood Purif"},{"key":"R10-20240807","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1111\/aor.13952","article-title":"Impact of CytoSorb on kinetics of vancomycin and bivalirudin in critically ill patients.","volume":"45","author":"Scandroglio","year":"2021","journal-title":"Artif Organs"},{"key":"R12-20240807","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1159\/000510292","article-title":"Successful treatment of severe digitoxin intoxication with CytoSorb\u00ae hemoadsorption.","volume":"50","author":"Breuer","year":"2021","journal-title":"Blood Purif"},{"key":"R13-20240807","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/0391398818812601","article-title":"In vitro removal of anti-infective agents by a novel cytokine adsorbent system.","volume":"42","author":"K\u00f6nig","year":"2019","journal-title":"Int J Artif Organs"},{"key":"R14-20240807","first-page":"1905871","article-title":"Cardiogenic shock in a hemodialyzed patient on flecainide: Treatment with intravenous fat emulsion, extracorporeal cardiac life support, and CytoSorb\u00ae hemoadsorption.","volume":"2019","author":"De Schryver","year":"2019","journal-title":"Case Rep Cardiol"},{"key":"R15-20240807","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40560-017-0208-1","article-title":"Effect of extracorporeal cytokine removal on vascular barrier function in a septic shock patient.","volume":"5","author":"David","year":"2017","journal-title":"J Intensive Care"},{"key":"R16-20240807","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1177\/0391398819831303","article-title":"Clindamycin clearance during Cytosorb\u00ae hemoadsorption: A case report and pharmacokinetic study.","volume":"42","author":"Poli","year":"2019","journal-title":"Int J Artif Organs"},{"key":"R17-20240807","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1093\/jac\/dkv068","article-title":"Can cytokine adsorber treatment affect antibiotic concentrations? A case report.","volume":"70","author":"Zoller","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"R18-20240807","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ijcard.2019.06.078","article-title":"Removal of dabigatran using sorbent hemadsorption.","volume":"293","author":"Angheloiu","year":"2019","journal-title":"Int J Cardiol"},{"key":"R19-20240807","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1177\/0391398820917151","article-title":"Elimination of glycopeptide antibiotics by cytokine hemoadsorption in patients with septic shock: A study of three cases.","volume":"43","author":"Dimski","year":"2020","journal-title":"Int J Artif Organs"},{"key":"R20-20240807","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s40268-020-00308-1","article-title":"In-vitro sorbent-mediated removal of edoxaban from human plasma and albumin solution.","volume":"20","author":"Angheloiu","year":"2020","journal-title":"Drugs R D"},{"key":"R21-20240807","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1177\/0391398819837539","article-title":"CytoSorb\u00ae hemoadsorption and mechanical circulatory support in a newborn with refractory shock after congenital heart surgery.","volume":"42","author":"Perez","year":"2019","journal-title":"Int J Artif Organs"},{"key":"R22-20240807","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1177\/0267659120967827","article-title":"Cytosorb\u00ae hemoadsorption of apixaban during emergent cardio-pulmonary bypass: A case report.","volume":"36","author":"Mendes","year":"2021","journal-title":"Perfusion"},{"key":"R23-20240807","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.carrev.2013.03.001","article-title":"In vitro catheter and sorbent-based method for clearance of radiocontrast material during cerebral interventions.","volume":"14","author":"Angheloiu","year":"2013","journal-title":"Cardiovasc Revasc Med"},{"key":"R24-20240807","doi-asserted-by":"crossref","first-page":"e00743","DOI":"10.1002\/prp2.743","article-title":"Hemoadsorption eliminates remdesivir from the circulation: Implications for the treatment of COVID-19.","volume":"9","author":"Biever","year":"2021","journal-title":"Pharmacol Res Perspect"},{"key":"R25-20240807","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1159\/000484923","article-title":"Extracorporeal hemoperfusion as a potential therapeutic option for critical accumulation of rivaroxaban.","volume":"45","author":"Koertge","year":"2018","journal-title":"Blood Purif"},{"key":"R26-20240807","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jacbts.2017.01.007","article-title":"Ticagrelor removal from human blood.","volume":"2","author":"Angheloiu","year":"2017","journal-title":"JACC Basic Transl Sci"},{"key":"R28-20240807","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1007\/s00134-021-06487-y","article-title":"No clinically relevant removal of meropenem by cytokine adsorber CytoSorb\u00ae in critically ill patients with sepsis or septic shock.","volume":"47","author":"Liebchen","year":"2021","journal-title":"Intensive Care Med"},{"key":"R29-20240807","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.2215\/CJN.00340118","article-title":"Clinical pharmacokinetics in kidney disease: Fundamental principles.","volume":"13","author":"Lea-Henry","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"R30-20240807","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2215\/CJN.05630614","article-title":"Pharmacokinetic assessment in patients receiving continuous RRT: Perspectives from the Kidney Health Initiative.","volume":"10","author":"Nolin","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"R31-20240807","doi-asserted-by":"crossref","first-page":"17054","DOI":"10.1021\/acs.langmuir.9b02318","article-title":"The binding of drug molecules to serum albumin: The effect of drug hydrophobicity on binding strength and protein desolvation.","volume":"35","author":"Al-Husseini","year":"2019","journal-title":"Langmuir"},{"key":"R32-20240807","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1097\/MAT.0000000000001513","article-title":"Impact of CytoSorb hemoadsorption on sedation requirements in patients with severe COVID-19 on venovenous extracorporeal membrane oxygenation.","volume":"67","author":"Lewis","year":"2021","journal-title":"ASAIO J"},{"key":"R33-20240807","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/sdi.12458","article-title":"Dose timing of aminoglycosides in hemodialysis patients: A pharmacology view.","volume":"29","author":"Eschenauer","year":"2016","journal-title":"Semin Dial"}],"container-title":["Critical Care Explorations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCE.0000000000000688","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T10:34:02Z","timestamp":1723026842000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CCE.0000000000000688"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":28,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/cce.0000000000000688","relation":{},"ISSN":["2639-8028"],"issn-type":[{"value":"2639-8028","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5]]}}}